NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only
 

Vaccination with Intradermal Recombinant Hepatitis B Vaccine in Healthcare Workers Who Fail to Respond to Intramuscular Vaccination.

PLAYFORD EG, HOGAN PG, BANSAL AS, DRUMMOND D, WHITBY M; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 373 (abstract no. 678).

Princess Alexandra Hosp., Brisbane, AUSTRALIA

BACKGROUND: Failure to respond to primary vaccination with intramuscular recombinant hepatitis B vaccine is reported to occur in 10% or more of healthcare workers (HCWs). Management of nonresponders is problematic as further intramuscularly-administered doses are successful in less than 50%. We studied the safety and the humoral and cellular immune responses associated with intradermally-administered recombinant hepatitis B vaccine in HCWs nonresponsive to repeated intramuscular vaccine doses.METHODS: Eighteen such HCWs were administered recombinant hepatitis B vaccine (5 microg/0.25 mL) intradermally every two weeks for a maximum of four doses. Humoral and cellular immune responses were assessed before, during, and after vaccination by determining hepatitis B surface antibody (aHBs) titres and peripheral blood mononuclear cell proliferative responses, and by the development of vaccine-associated delayed-type hypersensitivity skin reactions.RESULTS: Protective aHBs titres developed in 17 HCWs (94%). Nine HCWs (50%) developed aHBs titres >1000 IU/L and five (28%) 100-1000 IU/L. Three doses resulted in seroconversion of all responding HCWs and the highest mean antibody titre (590 IU/L). Evidence suggestive of cellular immunity was present in eight HCWs (44%) before intradermal vaccination, and in all responding HCWs after vaccination. The vaccine was well tolerated.CONCLUSIONS: Intradermally-administered recombinant hepatitis B vaccine induced protective aHBs titres and cellular immune responses in greater than 90% of HCWs previously nonresponsive to intramuscular vaccination.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Health Personnel
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Hypersensitivity, Delayed
  • Immunity, Cellular
  • Vaccination
  • immunology
Other ID:
  • GWAIDS0008081
UI: 102245578

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov